UNCYHIGH SIGNALREGULATORY10-K

UNCY received an FDA Complete Response Letter in June 2025 due to manufacturing deficiencies at a third-party vendor, delaying approval of their lead drug candidate oxylanthanum carbonate.

The CRL represents a significant setback for this biotech company's primary revenue opportunity, as FDA approval has been delayed due to manufacturing compliance issues outside of UNCY's direct control. While the company has engaged with the FDA through a Type A meeting to address the single identified deficiency, the approval timeline remains uncertain, creating substantial risk for a company dependent on this drug candidate for future growth.

Comparing 2026-03-30 vs 2025-03-31View on EDGAR →
FINANCIAL ANALYSIS

UNCY's financial position shows mixed signals with current assets growing substantially to $49.0M while total liabilities decreased meaningfully to $18.9M, suggesting improved liquidity. However, R&D expenses declined substantially from $20.0M to $9.1M, and revenue decreased 29% to $675K, indicating reduced operational activity. The improved net loss position reflects the lower R&D spending rather than operational improvements, while the company maintained dividend payments of $1.1M as previously committed upon potential FDA approval.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
-66.7%
$72K→$24K

Capex reduced 66.7% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Current Assets
Balance Sheet
+58.2%
$30.9M→$49.0M

Current assets grew 58.2% — improving short-term liquidity or inventory/receivables build.

SG&A Expense
P&L
+56.3%
$245K→$383K

SG&A up 56.3% — significant increase in sales or administrative costs, monitor impact on operating leverage.

Total Assets
Balance Sheet
+55.2%
$31.7M→$49.1M

Asset base grew 55.2% — expansion through organic growth, acquisitions, or capital deployment.

R&D Expense
P&L
-54.4%
$20.0M→$9.1M

R&D spending cut 54.4% — could signal cost discipline or concerning reduction in innovation investment.

Revenue
P&L
-29%
$951K→$675K

Revenue softened 29% — monitor whether this is cyclical or structural.

Net Income
P&L
+27.7%
-$36.7M→-$26.6M

Net income grew 27.7% — bottom-line growth signals improving overall business health.

Total Liabilities
Balance Sheet
-21.9%
$24.2M→$18.9M

Liabilities reduced 21.9% — deleveraging improves balance sheet strength and financial flexibility.

Dividends Paid
Cash Flow
+21.7%
$900K→$1.1M

Dividend payments increased 21.7% — management confidence in sustained cash generation.

Current Liabilities
Balance Sheet
-21.5%
$24.1M→$18.9M

Current liabilities reduced — improved short-term financial position and working capital health.

LANGUAGE CHANGES
NEW — 2026-03-30
PRIOR — 2025-03-31
ADDED
You may experience dilution, subordination of stockholder rights, preferences, and privileges, and decrease in market price of our common stock as a result of our private placement in March 2023.
We do not intend to pay cash dividends on our shares of common stock so any returns will be limited to the value of our shares, except we have agreed to pay cash dividends in the event oxylanthanum carbonate is approved by the FDA and commercial sales is commenced - iv - PART I Throughout this Annual Report on Form 10-K, references to we, our, us, the Company, Unicycive, or Unicycive Therapeutics refer to Unicycive Therapeutics, Inc.
In September 2024, we submitted a New Drug Application (NDA) for OLC to the FDA.
In November 2024 we announced the FDA had accepted its NDA and set a Prescription Drug User Fee Act (PDUFA) target action date of June 28, 2025.
In June 2025, the FDA issued us a Complete Response Letter (CRL) notifying us that a third-party manufacturing vendor of its main contract development and manufacturing organization (CDMO) was cited for deficiencies following a cGMP inspection.
+7 more — sign up free →
REMOVED
You may experience dilution, subordination of stockholder rights, preferences, and privileges, and decrease in market price of our common stock as a result of our private placements in March 2023 and March 2024.
We do not intend to pay cash dividends on our shares of common stock so any returns will be limited to the value of our shares, except we have agreed to pay cash dividends in the event ( Oxylanthanum Carbonate ) is approved by the FDA and commercial sales is commenced.
- iv - PART I Throughout this Annual Report on Form 10-K, references to we, our, us, the Company, Unicycive, or Unicycive Therapeutics refer to Unicycive Therapeutics, Inc.
The Company has submitted a New Drug Application (NDA) and has an assigned Prescription Drug User Fee Act (PDUFA) date of June 28, 2025.
Hyperphosphatemia is also a major cause of morbidity in CKD patients, which increases the economic and clinical burden on patients and the health system and results in Medicare expenditures of $70 billion in the U.S.
+7 more — sign up free →
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →